183 related articles for article (PubMed ID: 28389619)
1. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
[TBL] [Abstract][Full Text] [Related]
2. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
Kaipainen A; Zhang A; Gil da Costa RM; Lucas J; Marck B; Matsumoto AM; Morrissey C; True LD; Mostaghel EA; Nelson PS
Prostate; 2019 Sep; 79(13):1530-1542. PubMed ID: 31376206
[TBL] [Abstract][Full Text] [Related]
3. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
[TBL] [Abstract][Full Text] [Related]
6. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
7. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
[TBL] [Abstract][Full Text] [Related]
8. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
[TBL] [Abstract][Full Text] [Related]
9. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
10. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
11. Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens.
Li CY; Gupta A; Gáborik Z; Kis E; Prasad B
Mol Pharmacol; 2020 Sep; 98(3):234-242. PubMed ID: 32587096
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
Knuuttila M; Mehmood A; Huhtaniemi R; Yatkin E; Häkkinen MR; Oksala R; Laajala TD; Ryberg H; Handelsman DJ; Aittokallio T; Auriola S; Ohlsson C; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Am J Pathol; 2018 Jan; 188(1):216-228. PubMed ID: 29126837
[TBL] [Abstract][Full Text] [Related]
14. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
[TBL] [Abstract][Full Text] [Related]
15. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
16. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
17. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
19. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract][Full Text] [Related]
20. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]